|
1.
|
Hanley AJ, Williams K, Festa A,
Wagenknecht LE, D'Agostino RB Jr and Haffner SM: Liver markers and
development of the metabolic syndrome: the insulin resistance
atherosclerosis study. Diabetes. 54:3140–3147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Mulhall BP, Ong JP and Younossi ZM:
Non-alcoholic fatty liver disease: an overview. J Gastroenterol
Hepatol. 17:1136–1143. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Angulo P and Lindor KD: Non-alcoholic
fatty liver disease. J Gastroenterol Hepatol. 17:S186–S190. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Grant LM and Lisker-Melman M: Nonalcoholic
fatty liver disease. Ann Hepatol. 3:93–99. 2004.PubMed/NCBI
|
|
5.
|
Diehl AM, Goodman Z and Ishak KG:
Alcohollike liver disease in nonalcoholics. A clinical and
histologic comparison with alcohol-induced liver injury.
Gastroenterology. 95:1056–1062. 1988.PubMed/NCBI
|
|
6.
|
Bellentani S, Saccoccio G, Masutti F, et
al: Prevalence of and risk factors for hepatic steatosis in
Northern Italy. Ann Intern Med. 132:112–117. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Akbar DH and Kawther AH: Nonalcoholic
fatty liver disease in Saudi type 2 diabetic subjects attending a
medical outpatient clinic: prevalence and general characteristics.
Diabetes Care. 26:3351–3352. 2003. View Article : Google Scholar
|
|
8.
|
Gupte P, Amarapurkar D, Agal S, et al:
Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J
Gastroenterol Hepatol. 19:854–858. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Assy N, Kaita K, Mymin D, Levy C, Rosser B
and Minuk G: Fatty infiltration of liver in hyperlipidemic
patients. Dig Dis Sci. 45:1929–1934. 2000. View Article : Google Scholar
|
|
10.
|
Donati G, Stagni B, Piscaglia F, et al:
Increased prevalence of fatty liver in arterial hypertensive
patients with normal liver enzymes: role of insulin resistance.
Gut. 53:1020–1023. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Reaven GM: Banting lecture 1988. Role of
insulin resistance in human disease. Diabetes. 37:1595–1607. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Neuschwander-Tetri BA and Caldwell SH:
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic
Conference. Hepatology. 37:1202–1219. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Preuss HG: Effects of glucose/insulin
perturbations on aging and chronic disorders of aging: the
evidence. J Am Coll Nutr. 16:397–403. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Balaban YH, Sumer H, Simsek H, Us D and
Tatar G: Metabolic syndrome, non-alcoholic steatohepatitis (NASH),
and hepatocyte growth factor (HGF). Ann Hepatol. 5:109–114.
2006.PubMed/NCBI
|
|
15.
|
Lee DH, Ha MH, Kim JH, et al:
Gamma-glutamyltransferase and diabetes – a 4 year follow-up study.
Diabetologia. 46:359–364. 2003.
|
|
16.
|
Czaja MJ: Liver injury in the setting of
steatosis: crosstalk between adipokine and cytokine. Hepatology.
40:19–22. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Matsuzawa Y, Funahashi T and Nakamura T:
Molecular mechanism of metabolic syndrome X: contribution of
adipocytokines adipocyte-derived bioactive substances. Ann NY Acad
Sci. 892:146–154. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Day CP and James OF: Steatohepatitis: a
tale of two ‘hits’? Gastroenterology. 114:842–845. 1998.
|
|
19.
|
Gentile CL and Pagliassotti MJ: The role
of fatty acids in the development and progression of nonalcoholic
fatty liver disease. J Nutr Biochem. 19:567–576. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Mehta K, van Thiel DH, Shah N and Mobarhan
S: Non-alcoholic fatty liver disease: pathogenesis and the role of
antioxidants. Nutr Rev. 60:289–293. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Fain JN, Madan AK, Hiler ML, Cheema P and
Bahouth SW: Comparison of the release of adipokines by adipose
tissue, adipose tissue matrix, and adipocytes from visceral and
subcutaneous abdominal adipose tissues of obese humans.
Endocrinology. 145:2273–2282. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Kershaw EE and Flier JS: Adipose tissue as
an endocrine organ. J Clin Endocrinol Metab. 89:2548–2556. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Executive summary of the third report of
the National Cholesterol Education Program (NCEP) expert panel on
detection, evaluation, and treatment of high blood cholesterol in
adults (Adult Treatment Panel III). Jama. 285:2486–2497. 2001.
View Article : Google Scholar
|
|
24.
|
Clinical guidelines on the identification,
evaluation, and treatment of overweight and obesity in adults - the
evidence report. National Institutes of Health. Obes Res. 6(Suppl
2): S51–S209. 1998.PubMed/NCBI
|
|
25.
|
The sixth report of the Joint National
Committee on prevention, detection, evaluation, and treatment of
high blood pressure. Arch Intern Med. 157:2413–2446. 1997.
View Article : Google Scholar
|
|
26.
|
Marchesini G, Avagnina S, Barantani EG, et
al: Aminotransferase and gamma-glutamyltranspeptidase levels in
obesity are associated with insulin resistance and the metabolic
syndrome. J Endocrinol Invest. 28:333–339. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
James OF and Day CP: Non-alcoholic
steatohepatitis (NASH): a disease of emerging identity and
importance. J Hepatol. 29:495–501. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Lee YS, Kek BL, Poh LK, Saw SM and Loke
KY: Association of raised liver transaminases with physical
inactivity, increased waist-hip ratio, and other metabolic
morbidities in severely obese children. J Pediatr Gastroenterol
Nutr. 47:172–178. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Nannipieri M, Gonzales C, Baldi S, et al:
Liver enzymes, the metabolic syndrome, and incident diabetes: the
Mexico City diabetes study. Diabetes Care. 28:1757–1762. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Medina J, Fernandez-Salazar LI,
Garcia-Buey L and Moreno-Otero R: Approach to the pathogenesis and
treatment of non-alcoholic steatohepatitis. Diabetes Care.
27:2057–2066. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Yavuz BB, Yavuz B, Halil M, et al: Serum
elevated gamma glutamyltransferase levels may be a marker for
oxidative stress in Alzheimer's disease. Int Psychogeriatr.
20:815–823. 2008.PubMed/NCBI
|
|
32.
|
Karp DR, Shimooku K and Lipsky PE:
Expression of gamma-glutamyl transpeptidase protects ramos B cells
from oxidation-induced cell death. J Biol Chem. 276:3798–3804.
2001. View Article : Google Scholar : PubMed/NCBI
|
